The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global autoimmune disease diagnosis market was valued at US$ 3.5 Billion in 2021.
Sudden outbreak of the COVID-19 pandemic had led to the postponement of numerous elective diagnosis procedures, including blood tests, biopsy, X-rays, physical therapy, etc., for reducing the risk of coronavirus infection upon interaction with healthcare professionals or equipment.
We expect the global autoimmune disease diagnosis market to exhibit a CAGR of 6.4% during 2022-2027.
The rising adoption of numerous advanced technologies to conduct multiple tests simultaneously with faster and accurate results is currently driving the global autoimmune disease diagnosis market.
Based on the product type, the market has been bifurcated into consumables and assay kits, and instruments. Currently, consumables and assay kits hold the majority of the total market share.
Based on the disease type, the market can be divided into systemic autoimmune disease and localized autoimmune disease. Amongst these, localized autoimmune disease currently accounts for the majority of the total market share.
Based on the test type, the market has been segmented into routine laboratory tests, inflammatory markers, autoantibodies and immunologic tests, and others. Currently, routine laboratory tests exhibit a clear dominance in the market.
On a regional level, the market has been segmented into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global autoimmune disease diagnosis market include Abbott Laboratories, AESKU.GROUP, Danaher Corp., bioMérieux SA, Bio-Rad Laboratories, Inc., PerkinElmer Inc., Hemagen Diagnostics, Inc., Inova Diagnostics, Inc., Myriad Genetics, Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, SQI Diagnostics, Thermo Fisher Scientific Inc., and Trinity Biotech plc.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at